articleThe LancetNov 6, 2014Closed access

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

BABrent A. Neuschwander‐TetriRLRohit LoombaAJArun J. SanyalJEJoel E. LavineMLMark L. Van Natta

Saint Louis University · University of California, San Diego · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

2,176
total citations
FWCI
119.26
Percentile
100%
References
31
Citations per year

Authors

18

Topics & keywords

Topics
Keywords
  • Obeticholic acid
  • Medicine
  • Internal medicine
  • Farnesoid X receptor
  • Steatohepatitis
  • Gastroenterology
  • Placebo
  • Fatty liver
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding